You are here

Cosentyx

FDA approves Novartis Cosentyx as the first new biologic treatment option for hidradenitis suppurativa patients in nearly a decade

Yahoo Finance

Wed, 11/1/23 - 10:14 pm

Novartis Wins FDA Approval for Intravenous Cosentyx Formulation

BioSpace

Mon, 10/9/23 - 10:14 am

ankylosing spondylitis

psoriatic arthritis

non-radiographic axial spondyloarthritis

In upcoming skin disease clash, doctors see Novartis' Cosentyx as an underdog

Fierce Pharma

Tue, 04/11/23 - 10:04 am

hidradenitis suppurativa

Novartis touts Cosentyx win in debilitating skin condition. Can it challenge AbbVie's Humira?

Fierce Pharma

Tue, 09/13/22 - 08:03 pm

hidradenitis suppurativa

FDA approves Novartis’ Cosentyx to treat arthritis in children and adolescents

Pharmaceutical Business Review

Sun, 12/26/21 - 11:17 pm

The top 15 blockbuster patent expirations coming this decade

Fierce Pharma

Mon, 07/12/21 - 11:08 am

Novartis stakes another PhIII win for Cosentyx, goes deeper into pediatric markets

Endpoints

Wed, 06/2/21 - 10:54 am

juvenile idiopathic arthritis

Novartis puts spokesceleb Cyndi Lauper in host chair for life-with-psoriasis podcast

Fierce Pharma

Sat, 08/29/20 - 11:38 pm

celebrity endorsements

UCB touts another psoriasis win, this time over Cosentyx, as they look to break into packed market

Endpoints

Fri, 07/24/20 - 11:17 am

Eli Lilly’s Mirikizumab Hits the Mark in Phase III Study, Bests Cosentyx

BioSpace

Sat, 07/18/20 - 12:17 pm

clinical trials

Novartis gets FDA approval for Cosentyx to treat active non-radiographic axial spondyloarthritis

Pharmaceutical Business Review

Thu, 06/18/20 - 10:32 am

non-radiographic axial spondyloarthritis

Novartis takes aim at Eli Lilly with Cosentyx FDA nod in spondyloarthritis

Fierce Pharma

Wed, 06/17/20 - 09:57 am

spondyloarthritis

UCB’s growth driver squares up against the competition

EP Vantage

Thu, 06/11/20 - 12:20 pm

clinical trials

Eli Lilly's Taltz beats Novartis to the punch with FDA approval in spondyloarthritis

Fierce Pharma

Mon, 06/1/20 - 11:32 pm

axial spondyloarthritis

AbbVie and Boehringer Ingelheim's Skyrizi Beat Novartis' Cosentyx in Plaque Psoriasis

Motley Fool

Wed, 01/15/20 - 10:56 am

Boehringer Ingelheim

Novartis’ Cosentyx Narrowly Misses Beating Out AbbVie’s Humira in Arthritis Trial

BioSpace

Fri, 11/1/19 - 11:50 am

psoriatic arthritis

Novartis stacks more positive PhIII data on Cosentyx franchise — eyeing approval in non-radiographic axial spondyloarthritis

Endpoints

Wed, 10/2/19 - 10:54 am

axial spondyloarthritis

Novartis’ Cosentyx heads for fourth indication after supportive data in early ankylosing spondylitis

Pharmaforum

Tue, 09/17/19 - 10:18 am

ankylosing spondylitis

Novartis’ Cosentyx achieves primary and secondary endpoints in psoriatic arthritis study

Pharmaceutical Business Review

Wed, 06/12/19 - 09:57 am

clinical trials

psoriatic arthritis

Novartis data confirm rapid response and high efficacy of Cosentyx in psoriasis patients for first time in China

Pharmaceutical Business Review

Tue, 03/5/19 - 10:00 am

Pages